Faruqi & Faruqi, LLP Announces the Investigation of Omnicare, Inc. (OCR) Over the Proposed Sale of the Company to CVS Health Corporation
Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Omnicare, Inc. (“Omnicare” or the “Company”) (NYSE: OCR) for potential breaches of fiduciary duties in connection with the sale of the Company to CVS Health Corporation for approximately $12.7 billion. The Company’s stockholders will only receive $98 per share in cash for each share of Omnicare common stock they own. However, at least one analyst has set a price target of $104.00 for Omnicare shares, significantly higher than the offer price.
If you own common stock in Omnicare and wish to obtain additional information and protect your investments free of charge, please contact Juan E. Monteverde, Esq. either via e-mail at email@example.com or by telephone at (877) 247-4292 or (212) 983-9330.
Please tell us about yourself by completing the form below and we will provide you with additional
information at no cost to you on how to join the Class Action.
* The submission of this form does not create an attorney-client relationship.
Faruqi & Faruqi, LLP
685 Third Avenue 26th Floor
New York, NY 10017
Tel: (212) 983-9330
If you have information regarding this case that you would like to make available, please click here to contact us about our investigation.